IRADIMED CEO-linked trust sells 7,500 shares

IRADIMED CORP director and CEO Roger E. Susi reported planned insider sales of company stock through a family trust.

Rhea-AI Filing Summary

IRADIMED CORP director and CEO Roger E. Susi reported planned insider sales of company stock through a family trust. A total of 7,500 shares of common stock were sold on March 6, 2026 by the Phillip Susi 2008 Dynasty Trust in open-market transactions at weighted average prices of $98.25 and $99.12 per share, under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, indirect holdings reported for related trusts included 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust.

Insider Trade Summary

Net Seller: 7,500 shares

Net Sell 4 txns

Insider Susi Roger E.

Role CEO, PRESIDENT, CHAIRMAN

Sold 7,500 shs ($738K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,300	$98.25	$619K
Sale	Common Stock	1,200	$99.12	$119K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,255,000 shares (Indirect, By Phillip Susi 2008 Dynasty Trust); Common Stock — 162,950 shares (Indirect, By Roger E. Susi Revocable Trust); Common Stock — 2,062,500 shares (Indirect, By Matthew Susi 2008 Dynasty Trust)

Footnotes (4)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $98.00 to $99.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F3. This transaction was executed in multiple trades at prices ranging from $99.01 to $99.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IRADIMED (IRMD) insider Roger E. Susi report on this Form 4?

Roger E. Susi reported indirect sales of IRADIMED common stock by a related trust. The Form 4 shows 7,500 shares sold in open-market transactions on March 6, 2026, while several trusts continue to hold substantial indirect positions after the reported trades.

How many IRADIMED (IRMD) shares were sold and at what prices?

The filing reports 7,500 IRADIMED shares sold indirectly by a family trust. Sales were executed in multiple trades at weighted average prices of $98.25 and $99.12 per share, within disclosed ranges between $98.00 and $99.22 on March 6, 2026.

Who actually sold IRADIMED (IRMD) shares in this insider transaction?

The sales were made by the Phillip Susi 2008 Dynasty Trust, an entity associated with Roger E. Susi. The reporting person lists this as indirect ownership and specifically disclaims beneficial ownership except to the extent of any pecuniary interest in the securities held by the trust.

Was the IRADIMED (IRMD) insider sale part of a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan. This trading plan was adopted by the reporting person on November 5, 2025, providing a pre-arranged framework for executing trades according to predetermined instructions.

What IRADIMED (IRMD) shareholdings remain after the reported transactions?

After the March 6, 2026 transactions, the filing reports 162,950 shares held indirectly by the Roger E. Susi Revocable Trust. It also shows 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust as part of the reporting person’s overall indirect positions.

How does the Form 4 describe price ranges for the IRADIMED (IRMD) sales?

The Form 4 notes that individual trades were executed across price ranges. One group of trades occurred between $98.00 and $99.00, and another between $99.01 and $99.22, with reported weighted average sale prices of $98.25 and $99.12 respectively for disclosure purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		S(1)		6,300	D	$98.25(2)	2,256,200	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	03/06/2026		S(1)		1,200	D	$99.12(3)	2,255,000	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(4)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $98.00 to $99.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $99.01 to $99.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.